Purpose: To evaluate retinal sensitivity in children who are on hydroxychloroquine (HCQ) for systemic lupus erythematosus using microperimetry and compare the results with those of the Humphrey visual field (HVF) 10-2 and spectral-domain optical coherence tomography (SD-OCT). Procedure: A case-control cross-sectional study including 19 patients (less than 18 years old) on HCQ for at least 5 years. Controls were 21 normal children. Participants underwent a complete ophthalmic examination, then were investigated using HVF 10-2, SD-OCT, and microperimetry. Results: Ocular examination revealed no abnormalities. The overall mean microperimetry sensitivity of the patients (15.75 dB) was not significantly different from that of the controls (16.35 dB). The HVF 10-2 showed a significant difference in the mean deviation of the patients. Conclusions and Message: Microperimetry was not more revealing than HVF 10-2 and SD-OCT. Larger studies are required to compare the diagnostic accuracy of screening modalities of retinal toxicity in children on HCQ.

Keywords:
Children, Retinal toxicity, Microperimetry, Optical coherence tomography, Scanning laser ophthalmoscope
1.
Modjtahedi BS, Movassagh N, Gandhi N, Morse LS, Maibach HI: Screening for hydroxychloroquine toxicity in children. Cutan Ocul Toxicol 2013;32:344.
2.
Marmor MF, Kellner U, Lai TY, Lyons J, Mieler WF: Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-422.
3.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF: Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016;123:1386-1394.
4.
Rohrschneider K, Bltmann S, Springer C: Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Prog Retin Eye Res 2008;27:536-548.
5.
Menke MN, Sato E, Van De Velde FJ, Feke GT: Combined use of SLO microperimetry and OCT for retinal functional and structural testing. Graefes Arch Clin Exp Ophthalmol 2006;244:634-638.
6.
Hochberg MC: Updating the American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
7.
Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF: Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. Eye 2013;27:1044-1052.
8.
Martínez-Costa L, VictoriaIbañez M, Murcia-Bello C, Epifanio I, Verdejo-Gimeno C, Beltrán-Catalán E, Marco-Ventura P: Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. Can J Ophthalmol 2013;48:400-405.
9.
Melles RB, Marmor MF: The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453-1460.
10.
Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, Yoo B, Koo BS, et al: Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015;122:1252-1256.
11.
Anderson C, Blaha GR, Marx JL: Humphrey visual field findings in hydroxychloroquine toxicity. Eye 2011;25:1535-1545.
12.
Spaide RF, Curcio CA: Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 2011;31:1609-1619.
13.
Marmor MF: Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 2012;130:461-469.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.